Who Paid My Doc
Michael Jardula
Internal Medicine Palm Springs, CA Medical Doctor
NPI 1346222510 CMS profile 196394
275 N El Cielo, Palm Springs, CA 92262
General payments
$10,239
Research payments
$52,248
Ownership & investment interest
$0
Research they led as principal investigator
$4,244,526
Through program year 2025, Michael Jardula of Palm Springs, CA is reported in the CMS Open Payments database as having received $10,239 across 296 general payments and $52,248 in research payments paid to them. Separately, studies naming them as principal investigator received $4,244,526 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $391 | 17 | |
| 2025 | Research | $95 | 1 | |
| 2024 | General | $3,499 | 76 | |
| 2024 | Research | $45,872 | 3 | |
| 2023 | General | $2,250 | 44 | |
| 2022 | General | $797 | 42 | |
| 2022 | Research | $3,841 | 15 | |
| 2021 | General | $591 | 27 | |
| 2020 | General | $244 | 15 | |
| 2020 | Research | $1,330 | 1 | |
| 2019 | General | $2,468 | 75 | |
| 2019 | Research | $1,110 | 11 |
Beside peers
- Michael Jardula
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Michael Jardula were reported at $391. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Michael Jardula | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,468 | $159 | $48–$570 | $163 |
| 2020 | $244 | $119 | $33–$402 | $114 |
| 2021 | $591 | $135 | $37–$521 | $132 |
| 2022 | $797 | $141 | $42–$496 | $149 |
| 2023 | $2,250 | $149 | $45–$519 | $160 |
| 2024 | $3,499 | $154 | $47–$537 | $164 |
| 2025 | $391 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 237 drugsPart D claims
19,299
Drug cost
$5,046,975
Branded share of claims
23.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 252 | $1,257,879 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 123 | $556,116 | |
| Serostim Somatropin | Brand | 25 | $514,468 | |
| Cabenuva Cabotegravir/Rilpivirine | Brand | 32 | $210,093 | |
| Ozempic Semaglutide | Brand | 165 | $194,966 | |
| Eliquis Apixaban | Brand | 142 | $177,448 | |
| Jardiance Empagliflozin | Brand | 116 | $150,643 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 31 | $144,222 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 34 | $140,341 | |
| Mounjaro Tirzepatide | Brand | 89 | $129,070 |
The 10 drugs with the highest cost, of 237 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 22 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DOVATO |
|
$222 | 33 | — |
| APRETUDE |
|
$121 | — | — |
| Ozempic |
|
$65 | 165 | — |
| VOQUEZNA |
|
$64 | — | — |
| UBRELVY |
|
$56 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 22 in the dashboard with a free accountRecords
327 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in California
Andrew Cheng
Internal Medicine · South San Francisco, CA
Tung Ngo
Internal Medicine · Newport Beach, CA
Christian Eversull
Internal Medicine · Stanford, CA
Christian Sandrock
Internal Medicine · Sacramento, CA
Hatim Husain
Internal Medicine · San Diego, CA
Teck Ling
Internal Medicine · Palo Alto, CA
Related records
Internal Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.